Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis‐associated inflammatory bowel disease (PSC‐IBD): A matched analysis from the Paediatric PSC Consortium

Summary Background Data on oral vancomycin for primary sclerosing cholangitis (PSC)‐associated inflammatory bowel disease (IBD) are limited. Aims Using data from the Paediatric PSC Consortium, to examine the effect of vancomycin on IBD activity. Methods In this retrospective multi‐centre cohort stud...

Full description

Saved in:
Bibliographic Details
Published inAlimentary pharmacology & therapeutics Vol. 59; no. 10; pp. 1236 - 1247
Main Authors Ricciuto, Amanda, Liu, Kuan, El‐Matary, Wael, Amin, Mansi, Amir, Achiya Z., Aumar, Madeleine, Auth, Marcus, Di Guglielmo, Matthew D., Druve Tavares Fagundes, Eleonora, Rodrigues Ferreira, Alexandre, Furuya, Katryn N., Gupta, Nitika, Guthery, Stephen, Horslen, Simon P., Jensen, Kyle, Kamath, Binita M., Kerkar, Nanda, Koot, B. G. P., Laborda, Trevor J., Lee, Christine K., Loomes, Kathleen M., Mack, Cara, Martinez, Mercedes, Montano‐Loza, Aldo, Ovchinsky, Nadia, Papadopoulou, Alexandra, Perito, Emily R., Sathya, Pushpa, Schwarz, Kathleen B., Shah, Uzma, Shteyer, Eyal, Soufi, Nisreen, Stevens, James Patrick, Taylor, Amy, Tessier, M. Elizabeth, Valentino, Pamela, Woynarowski, Marek, Deneau, Mark
Format Journal Article
LanguageEnglish
Published England Wiley Subscription Services, Inc 01.05.2024
Wiley
SeriesAlimentary Pharmacology and Therapeutics
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Summary Background Data on oral vancomycin for primary sclerosing cholangitis (PSC)‐associated inflammatory bowel disease (IBD) are limited. Aims Using data from the Paediatric PSC Consortium, to examine the effect of vancomycin on IBD activity. Methods In this retrospective multi‐centre cohort study, we matched vancomycin‐treated and untreated patients (1:3) based on IBD duration at the time of primary outcome assessment. The primary outcome was Physician Global Assessment (PGA) of IBD clinical activity after 1 year (±6 months) of vancomycin. We used generalised estimating equations (GEE) to examine the association between vancomycin and PGA remission, adjusting for IBD type, severity and medication exposures. Secondary outcomes included serum labs and endoscopic remission (global rating of no activity) among those with available data and also analysed with GEE. Results 113 PSC‐IBD patients received vancomycin (median age 12.7 years, 63% male). The matched cohort included 70 vancomycin‐treated and 210 untreated patients. Vancomycin was associated with greater odds of IBD clinical remission (odds ratio [OR] 3.52, 95% CI 1.97–6.31; adjusted OR [aOR] 5.24, 95% CI 2.68–10.22). Benefit was maintained in sensitivity analyses restricted to non‐transplanted patients and those with baseline moderate–severe PGA. Vancomycin was associated with increased odds of endoscopic remission (aOR 2.76, 95% CI 1.002–7.62; N = 101 with data), and with lower CRP (p = 0.03) and higher haemoglobin and albumin (both p < 0.01). Conclusion Vancomycin was associated with greater odds of IBD clinical and endoscopic remission. Additional, preferably randomised, controlled studies are needed to characterise efficacy using objective markers of mucosal inflammation, and to examine safety and define optimal dosing. Results of matched analysis of vancomycin‐treated and untreated children with PSC‐IBD from the Pediatric PSC Consortium, showing higher rates of clinical remission (unadjusted and adjusted for covariates including other medication exposure; in UC and CD) and endoscopic remission in the subset with endoscopic data available.
AbstractList BackgroundData on oral vancomycin for primary sclerosing cholangitis (PSC)‐associated inflammatory bowel disease (IBD) are limited.AimsUsing data from the Paediatric PSC Consortium, to examine the effect of vancomycin on IBD activity.MethodsIn this retrospective multi‐centre cohort study, we matched vancomycin‐treated and untreated patients (1:3) based on IBD duration at the time of primary outcome assessment. The primary outcome was Physician Global Assessment (PGA) of IBD clinical activity after 1 year (±6 months) of vancomycin. We used generalised estimating equations (GEE) to examine the association between vancomycin and PGA remission, adjusting for IBD type, severity and medication exposures. Secondary outcomes included serum labs and endoscopic remission (global rating of no activity) among those with available data and also analysed with GEE.Results113 PSC‐IBD patients received vancomycin (median age 12.7 years, 63% male). The matched cohort included 70 vancomycin‐treated and 210 untreated patients. Vancomycin was associated with greater odds of IBD clinical remission (odds ratio [OR] 3.52, 95% CI 1.97–6.31; adjusted OR [aOR] 5.24, 95% CI 2.68–10.22). Benefit was maintained in sensitivity analyses restricted to non‐transplanted patients and those with baseline moderate–severe PGA. Vancomycin was associated with increased odds of endoscopic remission (aOR 2.76, 95% CI 1.002–7.62; N = 101 with data), and with lower CRP (p = 0.03) and higher haemoglobin and albumin (both p < 0.01).ConclusionVancomycin was associated with greater odds of IBD clinical and endoscopic remission. Additional, preferably randomised, controlled studies are needed to characterise efficacy using objective markers of mucosal inflammation, and to examine safety and define optimal dosing.
Data on oral vancomycin for primary sclerosing cholangitis (PSC)-associated inflammatory bowel disease (IBD) are limited. Using data from the Paediatric PSC Consortium, to examine the effect of vancomycin on IBD activity. In this retrospective multi-centre cohort study, we matched vancomycin-treated and untreated patients (1:3) based on IBD duration at the time of primary outcome assessment. The primary outcome was Physician Global Assessment (PGA) of IBD clinical activity after 1 year (±6 months) of vancomycin. We used generalised estimating equations (GEE) to examine the association between vancomycin and PGA remission, adjusting for IBD type, severity and medication exposures. Secondary outcomes included serum labs and endoscopic remission (global rating of no activity) among those with available data and also analysed with GEE. 113 PSC-IBD patients received vancomycin (median age 12.7 years, 63% male). The matched cohort included 70 vancomycin-treated and 210 untreated patients. Vancomycin was associated with greater odds of IBD clinical remission (odds ratio [OR] 3.52, 95% CI 1.97-6.31; adjusted OR [aOR] 5.24, 95% CI 2.68-10.22). Benefit was maintained in sensitivity analyses restricted to non-transplanted patients and those with baseline moderate-severe PGA. Vancomycin was associated with increased odds of endoscopic remission (aOR 2.76, 95% CI 1.002-7.62; N = 101 with data), and with lower CRP (p = 0.03) and higher haemoglobin and albumin (both p < 0.01). Vancomycin was associated with greater odds of IBD clinical and endoscopic remission. Additional, preferably randomised, controlled studies are needed to characterise efficacy using objective markers of mucosal inflammation, and to examine safety and define optimal dosing.
Data on oral vancomycin for primary sclerosing cholangitis (PSC)-associated inflammatory bowel disease (IBD) are limited.BACKGROUNDData on oral vancomycin for primary sclerosing cholangitis (PSC)-associated inflammatory bowel disease (IBD) are limited.Using data from the Paediatric PSC Consortium, to examine the effect of vancomycin on IBD activity.AIMSUsing data from the Paediatric PSC Consortium, to examine the effect of vancomycin on IBD activity.In this retrospective multi-centre cohort study, we matched vancomycin-treated and untreated patients (1:3) based on IBD duration at the time of primary outcome assessment. The primary outcome was Physician Global Assessment (PGA) of IBD clinical activity after 1 year (±6 months) of vancomycin. We used generalised estimating equations (GEE) to examine the association between vancomycin and PGA remission, adjusting for IBD type, severity and medication exposures. Secondary outcomes included serum labs and endoscopic remission (global rating of no activity) among those with available data and also analysed with GEE.METHODSIn this retrospective multi-centre cohort study, we matched vancomycin-treated and untreated patients (1:3) based on IBD duration at the time of primary outcome assessment. The primary outcome was Physician Global Assessment (PGA) of IBD clinical activity after 1 year (±6 months) of vancomycin. We used generalised estimating equations (GEE) to examine the association between vancomycin and PGA remission, adjusting for IBD type, severity and medication exposures. Secondary outcomes included serum labs and endoscopic remission (global rating of no activity) among those with available data and also analysed with GEE.113 PSC-IBD patients received vancomycin (median age 12.7 years, 63% male). The matched cohort included 70 vancomycin-treated and 210 untreated patients. Vancomycin was associated with greater odds of IBD clinical remission (odds ratio [OR] 3.52, 95% CI 1.97-6.31; adjusted OR [aOR] 5.24, 95% CI 2.68-10.22). Benefit was maintained in sensitivity analyses restricted to non-transplanted patients and those with baseline moderate-severe PGA. Vancomycin was associated with increased odds of endoscopic remission (aOR 2.76, 95% CI 1.002-7.62; N = 101 with data), and with lower CRP (p = 0.03) and higher haemoglobin and albumin (both p < 0.01).RESULTS113 PSC-IBD patients received vancomycin (median age 12.7 years, 63% male). The matched cohort included 70 vancomycin-treated and 210 untreated patients. Vancomycin was associated with greater odds of IBD clinical remission (odds ratio [OR] 3.52, 95% CI 1.97-6.31; adjusted OR [aOR] 5.24, 95% CI 2.68-10.22). Benefit was maintained in sensitivity analyses restricted to non-transplanted patients and those with baseline moderate-severe PGA. Vancomycin was associated with increased odds of endoscopic remission (aOR 2.76, 95% CI 1.002-7.62; N = 101 with data), and with lower CRP (p = 0.03) and higher haemoglobin and albumin (both p < 0.01).Vancomycin was associated with greater odds of IBD clinical and endoscopic remission. Additional, preferably randomised, controlled studies are needed to characterise efficacy using objective markers of mucosal inflammation, and to examine safety and define optimal dosing.CONCLUSIONVancomycin was associated with greater odds of IBD clinical and endoscopic remission. Additional, preferably randomised, controlled studies are needed to characterise efficacy using objective markers of mucosal inflammation, and to examine safety and define optimal dosing.
Summary Background Data on oral vancomycin for primary sclerosing cholangitis (PSC)‐associated inflammatory bowel disease (IBD) are limited. Aims Using data from the Paediatric PSC Consortium, to examine the effect of vancomycin on IBD activity. Methods In this retrospective multi‐centre cohort study, we matched vancomycin‐treated and untreated patients (1:3) based on IBD duration at the time of primary outcome assessment. The primary outcome was Physician Global Assessment (PGA) of IBD clinical activity after 1 year (±6 months) of vancomycin. We used generalised estimating equations (GEE) to examine the association between vancomycin and PGA remission, adjusting for IBD type, severity and medication exposures. Secondary outcomes included serum labs and endoscopic remission (global rating of no activity) among those with available data and also analysed with GEE. Results 113 PSC‐IBD patients received vancomycin (median age 12.7 years, 63% male). The matched cohort included 70 vancomycin‐treated and 210 untreated patients. Vancomycin was associated with greater odds of IBD clinical remission (odds ratio [OR] 3.52, 95% CI 1.97–6.31; adjusted OR [aOR] 5.24, 95% CI 2.68–10.22). Benefit was maintained in sensitivity analyses restricted to non‐transplanted patients and those with baseline moderate–severe PGA. Vancomycin was associated with increased odds of endoscopic remission (aOR 2.76, 95% CI 1.002–7.62; N = 101 with data), and with lower CRP (p = 0.03) and higher haemoglobin and albumin (both p < 0.01). Conclusion Vancomycin was associated with greater odds of IBD clinical and endoscopic remission. Additional, preferably randomised, controlled studies are needed to characterise efficacy using objective markers of mucosal inflammation, and to examine safety and define optimal dosing. Results of matched analysis of vancomycin‐treated and untreated children with PSC‐IBD from the Pediatric PSC Consortium, showing higher rates of clinical remission (unadjusted and adjusted for covariates including other medication exposure; in UC and CD) and endoscopic remission in the subset with endoscopic data available.
Author Loomes, Kathleen M.
Liu, Kuan
Perito, Emily R.
Papadopoulou, Alexandra
Soufi, Nisreen
Amin, Mansi
Schwarz, Kathleen B.
El‐Matary, Wael
Laborda, Trevor J.
Ovchinsky, Nadia
Montano‐Loza, Aldo
Rodrigues Ferreira, Alexandre
Furuya, Katryn N.
Ricciuto, Amanda
Guthery, Stephen
Druve Tavares Fagundes, Eleonora
Taylor, Amy
Lee, Christine K.
Shteyer, Eyal
Woynarowski, Marek
Auth, Marcus
Shah, Uzma
Horslen, Simon P.
Koot, B. G. P.
Jensen, Kyle
Martinez, Mercedes
Di Guglielmo, Matthew D.
Deneau, Mark
Tessier, M. Elizabeth
Kamath, Binita M.
Mack, Cara
Valentino, Pamela
Gupta, Nitika
Sathya, Pushpa
Stevens, James Patrick
Amir, Achiya Z.
Aumar, Madeleine
Kerkar, Nanda
Author_xml – sequence: 1
  givenname: Amanda
  orcidid: 0000-0001-9538-3005
  surname: Ricciuto
  fullname: Ricciuto, Amanda
  email: amanda.ricciuto@sickkids.ca
  organization: University of Toronto
– sequence: 2
  givenname: Kuan
  surname: Liu
  fullname: Liu, Kuan
  organization: University of Toronto
– sequence: 3
  givenname: Wael
  surname: El‐Matary
  fullname: El‐Matary, Wael
  organization: Max Rady College of Medicine, Children's Hospital Research Institute of Manitoba
– sequence: 4
  givenname: Mansi
  surname: Amin
  fullname: Amin, Mansi
  organization: Duke University Medical Center
– sequence: 5
  givenname: Achiya Z.
  surname: Amir
  fullname: Amir, Achiya Z.
  organization: Tel‐Aviv University
– sequence: 6
  givenname: Madeleine
  surname: Aumar
  fullname: Aumar, Madeleine
  organization: CHU de Lille
– sequence: 7
  givenname: Marcus
  surname: Auth
  fullname: Auth, Marcus
  organization: University of Liverpool
– sequence: 8
  givenname: Matthew D.
  surname: Di Guglielmo
  fullname: Di Guglielmo, Matthew D.
  organization: Nemours Children's Health
– sequence: 9
  givenname: Eleonora
  surname: Druve Tavares Fagundes
  fullname: Druve Tavares Fagundes, Eleonora
  organization: Faculty of Medicine of Federal University of Minas Gerais (UFMG), Hospital das Clinicas of UFMG
– sequence: 10
  givenname: Alexandre
  surname: Rodrigues Ferreira
  fullname: Rodrigues Ferreira, Alexandre
  organization: Hospital das Clinicas of UFMG
– sequence: 11
  givenname: Katryn N.
  surname: Furuya
  fullname: Furuya, Katryn N.
  organization: University of Wisconsin‐Madison School of Medicine and Public Health
– sequence: 12
  givenname: Nitika
  surname: Gupta
  fullname: Gupta, Nitika
  organization: Emory University School of Medicine, Children's Healthcare of Atlanta
– sequence: 13
  givenname: Stephen
  surname: Guthery
  fullname: Guthery, Stephen
  organization: Intermountain Primary Children's Hospital, University of Utah
– sequence: 14
  givenname: Simon P.
  surname: Horslen
  fullname: Horslen, Simon P.
  organization: UPMC Children's Hospital of Pittsburgh
– sequence: 15
  givenname: Kyle
  surname: Jensen
  fullname: Jensen, Kyle
  organization: Intermountain Primary Children's Hospital, University of Utah
– sequence: 16
  givenname: Binita M.
  surname: Kamath
  fullname: Kamath, Binita M.
  organization: University of Toronto
– sequence: 17
  givenname: Nanda
  surname: Kerkar
  fullname: Kerkar, Nanda
  organization: Golisano Children's Hospital, University of Rochester Medical Center
– sequence: 18
  givenname: B. G. P.
  surname: Koot
  fullname: Koot, B. G. P.
  organization: University of Amsterdam
– sequence: 19
  givenname: Trevor J.
  surname: Laborda
  fullname: Laborda, Trevor J.
  organization: Intermountain Primary Children's Hospital, University of Utah
– sequence: 20
  givenname: Christine K.
  surname: Lee
  fullname: Lee, Christine K.
  organization: Boston Children's Hospital
– sequence: 21
  givenname: Kathleen M.
  surname: Loomes
  fullname: Loomes, Kathleen M.
  organization: The Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania
– sequence: 22
  givenname: Cara
  surname: Mack
  fullname: Mack, Cara
  organization: University of Colorado Anschutz Medical Campus, Children's Wisconsin, Medical College of Wisconsin
– sequence: 23
  givenname: Mercedes
  surname: Martinez
  fullname: Martinez, Mercedes
  organization: Columbia University Irving Medical Center, New York‐Presbyterian
– sequence: 24
  givenname: Aldo
  orcidid: 0000-0002-2511-7980
  surname: Montano‐Loza
  fullname: Montano‐Loza, Aldo
  organization: Zeidler Ledcor Centre, University of Alberta
– sequence: 25
  givenname: Nadia
  surname: Ovchinsky
  fullname: Ovchinsky, Nadia
  organization: NYU Grossman School of Medicine
– sequence: 26
  givenname: Alexandra
  surname: Papadopoulou
  fullname: Papadopoulou, Alexandra
  organization: Athens Children's Hospital “AGIA SOFIA”, University of Athens
– sequence: 27
  givenname: Emily R.
  surname: Perito
  fullname: Perito, Emily R.
  organization: University of California San Francisco
– sequence: 28
  givenname: Pushpa
  surname: Sathya
  fullname: Sathya, Pushpa
  organization: Memorial University of Newfoundland
– sequence: 29
  givenname: Kathleen B.
  surname: Schwarz
  fullname: Schwarz, Kathleen B.
  organization: Rady Children's Hospital San Diego
– sequence: 30
  givenname: Uzma
  surname: Shah
  fullname: Shah, Uzma
  organization: Henry Ford Health
– sequence: 31
  givenname: Eyal
  surname: Shteyer
  fullname: Shteyer, Eyal
  organization: Shaare Zedek Medical Center
– sequence: 32
  givenname: Nisreen
  surname: Soufi
  fullname: Soufi, Nisreen
  organization: Children's Hospital Los Angeles
– sequence: 33
  givenname: James Patrick
  surname: Stevens
  fullname: Stevens, James Patrick
  organization: Emory University School of Medicine
– sequence: 34
  givenname: Amy
  surname: Taylor
  fullname: Taylor, Amy
  organization: Cincinnati Children's Hospital Medical Center
– sequence: 35
  givenname: M. Elizabeth
  surname: Tessier
  fullname: Tessier, M. Elizabeth
  organization: Baylor College of Medicine, Texas Children's Hospital
– sequence: 36
  givenname: Pamela
  surname: Valentino
  fullname: Valentino, Pamela
  organization: University of Washington School of Medicine, Seattle Children's
– sequence: 37
  givenname: Marek
  surname: Woynarowski
  fullname: Woynarowski, Marek
  organization: Jan Kochanowski University
– sequence: 38
  givenname: Mark
  surname: Deneau
  fullname: Deneau, Mark
  organization: University of Colorado Anschutz Medical Campus, Children's Wisconsin, Medical College of Wisconsin
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38462727$$D View this record in MEDLINE/PubMed
https://hal.univ-lille.fr/hal-04690334$$DView record in HAL
BookMark eNp9kt1u0zAUgC00xLrBBS-ALHGzXWRz4sSOuevKzyZVWiXGteU4zurJsYudtOodj8AzIvEenNIyEBL4xrL1-Ts_PifoyAdvEHqZk4sc1qVaDRc5F5Q9QZOcsiorCGVHaEIKJrKizukxOknpgRDCOCmeoWNal6zgBZ-g77dRObxWXod-q63HNmGVUtBWDabFGzssse1XMazhZH3nVN-rIcQtbsLGONzaZFQyWDvrrQZVGAdQmQQwXkXbK0CTdiaGZP091svglL-3g03fvnz9I9J_3GeLjzOAb67enr_BUwyMXsIL5ZXbJsi3i6HHw9LghTIt2KLVGJ7gWfApxMGO_XP0tFMumReH_RR9ev_ubnadzW8_3Mym80zTmrOMU6IL3lFd6rZTFTFV3Zm8aSgRhCvRkpIKplRDatNw0Ylci4aRmldNoyvStfQUne-9S-XkoXoZlJXX07nc3ZGSCUJpuc6BPduz0NzPo0mD7G3SxkF7TBiTLERVFWz3UYC-_gt9CGOE8pOkkFMtGOP17-Aaep2i6R4zyInczYmEOZE_5wTYVwfj2PSmfSR_DQYAl3tgY53Z_tskp4u7vfIHTRHPrw
CitedBy_id crossref_primary_10_1007_s10620_024_08497_4
crossref_primary_10_1097_HEP_0000000000000926
Cites_doi 10.1080/00365521.2020.1787501
10.1136/gut.26.12.1380
10.1001/jama.2022.21383
10.1007/s12664-022-01286-9
10.1093/ibd/izad040
10.1016/j.cgh.2011.11.030
10.1136/gutjnl-2018-316599
10.1007/s10875-012-9801-1
10.1016/j.jhep.2017.07.022
10.1007/s12328-020-01296-0
10.2147/CEG.S186097
10.1136/gutjnl-2015-310500
10.1007/s11894-018-0620-2
10.1053/j.gastro.2020.12.058
10.1136/gutjnl-2012-302578
10.1055/s-0039-1688501
10.1016/j.cgh.2023.04.004
10.1007/s10620-023-07826-3
10.1097/HEP.0000000000000304
10.5223/pghn.2016.19.3.210
10.1093/ibd/izz027
10.1002/hep.29204
10.1093/ibd/izz298
10.3748/wjg.v26.i21.2768
10.1002/hep.31560
10.1007/s12328-020-01272-8
10.3389/fimmu.2022.829525
10.1097/MEG.0000000000001223
10.1097/HC9.0000000000000347
ContentType Journal Article
Copyright 2024 John Wiley & Sons Ltd.
Copyright © 2024 John Wiley & Sons Ltd.
Distributed under a Creative Commons Attribution 4.0 International License
Copyright_xml – notice: 2024 John Wiley & Sons Ltd.
– notice: Copyright © 2024 John Wiley & Sons Ltd.
– notice: Distributed under a Creative Commons Attribution 4.0 International License
CorporateAuthor Pediatric PSC Consortium
the Pediatric PSC Consortium
CorporateAuthor_xml – sequence: 0
  name: the Pediatric PSC Consortium
– name: Pediatric PSC Consortium
DBID NPM
AAYXX
CITATION
7T5
7TK
7U9
H94
M7N
7X8
1XC
DOI 10.1111/apt.17936
DatabaseName PubMed
CrossRef
Immunology Abstracts
Neurosciences Abstracts
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
Algology Mycology and Protozoology Abstracts (Microbiology C)
MEDLINE - Academic
Hyper Article en Ligne (HAL)
DatabaseTitle PubMed
CrossRef
AIDS and Cancer Research Abstracts
Immunology Abstracts
Virology and AIDS Abstracts
Neurosciences Abstracts
Algology Mycology and Protozoology Abstracts (Microbiology C)
MEDLINE - Academic
DatabaseTitleList AIDS and Cancer Research Abstracts
PubMed
MEDLINE - Academic


Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1365-2036
EndPage 1247
ExternalDocumentID oai_HAL_hal_04690334v1
10_1111_apt_17936
38462727
APT17936
Genre researchArticle
Journal Article
GrantInformation_xml – fundername: PSC Partners Seeking a Cure
GroupedDBID ---
.3N
.GA
.GJ
.Y3
05W
0R~
10A
1OB
1OC
23M
24P
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5VS
66C
6J9
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAKAS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABJNI
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZCM
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFRAH
AFZJQ
AHBTC
AHEFC
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BAWUL
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
D-6
D-7
D-E
D-F
DC6
DCZOG
DIK
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DTERQ
E3Z
EAD
EAP
EAS
EBC
EBD
EBS
EBX
EJD
EMB
EMK
EMOBN
EST
ESX
EX3
F00
F01
F04
F5P
FEDTE
FIJ
FUBAC
FZ0
G-S
G.N
GODZA
GX1
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IPNFZ
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK0
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
P6G
PALCI
Q.N
Q11
QB0
Q~Q
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
SV3
TEORI
TR2
TUS
UB1
V8K
V9Y
W8V
W99
WBKPD
WH7
WHWMO
WIH
WIJ
WIK
WIN
WOHZO
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
XG1
YOC
ZZTAW
~IA
~WT
NPM
AAMNL
AAYXX
ACRPL
ACYXJ
CITATION
7T5
7TK
7U9
H94
M7N
7X8
1XC
ID FETCH-LOGICAL-c3876-730c27f3c4cdfa50e58fe1bb30907a9d04396aab08eb79f91c9b60875bbc50fd3
IEDL.DBID DR2
ISSN 0269-2813
1365-2036
IngestDate Wed Oct 02 06:35:31 EDT 2024
Thu Dec 05 23:09:20 EST 2024
Thu Oct 10 19:11:07 EDT 2024
Fri Dec 06 04:48:52 EST 2024
Sat Nov 02 12:28:33 EDT 2024
Sat Aug 24 00:57:25 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 10
Language English
License 2024 John Wiley & Sons Ltd.
Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3876-730c27f3c4cdfa50e58fe1bb30907a9d04396aab08eb79f91c9b60875bbc50fd3
Notes Amanda Ricciuto and Kuan Liu co‐first authorship/equal contribution.
The Handling Editor for this article was Professor Peter Gibson, and it was accepted for publication after full peer‐review.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-2511-7980
0000-0001-9538-3005
PMID 38462727
PQID 3043896678
PQPubID 2045200
PageCount 12
ParticipantIDs hal_primary_oai_HAL_hal_04690334v1
proquest_miscellaneous_2955268462
proquest_journals_3043896678
crossref_primary_10_1111_apt_17936
pubmed_primary_38462727
wiley_primary_10_1111_apt_17936_APT17936
PublicationCentury 2000
PublicationDate May 2024
PublicationDateYYYYMMDD 2024-05-01
PublicationDate_xml – month: 05
  year: 2024
  text: May 2024
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Chichester
PublicationSeriesTitle Alimentary Pharmacology and Therapeutics
PublicationTitle Alimentary pharmacology & therapeutics
PublicationTitleAlternate Aliment Pharmacol Ther
PublicationYear 2024
Publisher Wiley Subscription Services, Inc
Wiley
Publisher_xml – name: Wiley Subscription Services, Inc
– name: Wiley
References 2023; 77
2016; 19
2017; 66
2013; 62
2019; 12
2017; 67
2019; 39
2021; 160
2022; 41
2020; 55
2018; 20
2021; 73
2012; 10
1985; 26
2021; 14
2023; 21
2023; 68
2013; 33
2023; 29
2024; 8
2019; 68
2019; 25
2022; 13
2020; 26
2018; 30
2022; 328
2016; 66
e_1_2_9_30_1
e_1_2_9_11_1
e_1_2_9_10_1
e_1_2_9_13_1
e_1_2_9_12_1
e_1_2_9_15_1
e_1_2_9_14_1
e_1_2_9_17_1
e_1_2_9_16_1
e_1_2_9_19_1
e_1_2_9_18_1
e_1_2_9_20_1
e_1_2_9_22_1
e_1_2_9_21_1
e_1_2_9_24_1
e_1_2_9_23_1
e_1_2_9_8_1
e_1_2_9_7_1
e_1_2_9_6_1
e_1_2_9_5_1
e_1_2_9_4_1
e_1_2_9_3_1
e_1_2_9_2_1
e_1_2_9_9_1
e_1_2_9_26_1
e_1_2_9_25_1
e_1_2_9_28_1
e_1_2_9_27_1
e_1_2_9_29_1
References_xml – volume: 25
  start-page: e90
  year: 2019
  end-page: e91
  article-title: Oral vancomycin induces and maintains remission of ulcerative colitis in the subset of patients with associated primary Sclerosing cholangitis
  publication-title: Inflamm Bowel Dis
– volume: 73
  start-page: 1061
  year: 2021
  end-page: 1073
  article-title: Oral vancomycin, ursodeoxycholic acid, or no therapy for pediatric primary sclerosing cholangitis: a matched analysis
  publication-title: Hepatology
– volume: 26
  start-page: 2768
  year: 2020
  end-page: 2780
  article-title: Gut microbiome in primary sclerosing cholangitis: a review
  publication-title: World J Gastroenterol
– volume: 8
  start-page: 8
  year: 2024
  article-title: Efficacy and safety of biologics in primary sclerosing cholangitis with inflammatory bowel disease: a systematic review and meta‐analysis
  publication-title: Hepatol Commun
– volume: 41
  start-page: 519
  year: 2022
  end-page: 524
  article-title: How frequent are vancomycin‐resistant enterococci in patients with primary sclerosing cholangitis and ulcerative colitis treated with oral vancomycin?
  publication-title: Indian J Gastroenterol
– volume: 29
  start-page: 837
  year: 2023
  end-page: 838
  article-title: Oral vancomycin induced and maintained clinical and endoscopic remission in ulcerative colitis and primary sclerosing cholangitis post‐liver transplantation
  publication-title: Inflamm Bowel Dis
– volume: 62
  start-page: 531
  year: 2013
  end-page: 539
  article-title: Connecting dysbiosis, bile‐acid dysmetabolism and gut inflammation in inflammatory bowel diseases
  publication-title: Gut
– volume: 68
  start-page: 1533
  year: 2019
  end-page: 1535
  article-title: Oral vancomycin induces clinical and mucosal remission of colitis in children with primary sclerosing cholangitis‐ulcerative colitis
  publication-title: Gut
– volume: 19
  start-page: 210
  year: 2016
  end-page: 213
  article-title: Oral vancomycin therapy in a child with primary Sclerosing cholangitis and severe ulcerative colitis
  publication-title: Pediatr Gastroenterol Hepatol Nutr
– volume: 10
  start-page: 417
  year: 2012
  end-page: 421.e2
  article-title: Validation and modification of simplified diagnostic criteria for autoimmune hepatitis in children
  publication-title: Clin Gastroenterol Hepatol
– volume: 160
  start-page: 1784
  year: 2021
  end-page: 1798.e0
  article-title: Altered gut microbial metabolism of essential nutrients in primary sclerosing cholangitis
  publication-title: Gastroenterology
– volume: 26
  start-page: 1733
  year: 2020
  end-page: 1742
  article-title: Antibiotic cocktail for pediatric acute severe colitis and the microbiome: the PRASCO randomized controlled trial
  publication-title: Inflamm Bowel Dis
– volume: 67
  start-page: 1298
  year: 2017
  end-page: 1323
  article-title: Primary sclerosing cholangitis—a comprehensive review
  publication-title: J Hepatol
– volume: 77
  start-page: E174
  year: 2023
  end-page: E175
  article-title: Letter to the editor: insurance should cover vancomycin for primary sclerosing cholangitis
  publication-title: Hepatology
– volume: 13
  year: 2022
  article-title: The emerging role of bile acids in the pathogenesis of inflammatory bowel disease
  publication-title: Front Immunol
– volume: 14
  start-page: 684
  year: 2021
  end-page: 689
  article-title: Successful response of primary sclerosing cholangitis and associated ulcerative colitis to oral vancomycin may depend on brand and personalized dose: report in an adolescent
  publication-title: Clin J Gastroenterol
– volume: 12
  start-page: 9
  year: 2019
  end-page: 19
  article-title: A pilot study of fecal bile acid and microbiota profiles in inflammatory bowel disease and primary sclerosing cholangitis
  publication-title: Clin Exp Gastroenterol
– volume: 26
  start-page: 1380
  year: 1985
  end-page: 1384
  article-title: Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis
  publication-title: Gut
– volume: 33
  start-page: 397
  year: 2013
  end-page: 406
  article-title: Immunomodulatory effect of vancomycin on Treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis
  publication-title: J Clin Immunol
– volume: 30
  start-page: 1247
  year: 2018
  end-page: 1252
  article-title: Oral vancomycin induces sustained deep remission in adult patients with ulcerative colitis and primary sclerosing cholangitis
  publication-title: Eur J Gastroenterol Hepatol
– volume: 68
  start-page: 1118
  year: 2023
  end-page: 1120
  article-title: Besting the biologics: vancomycin monotherapy for ulcerative colitis management in patients with primary sclerosing cholangitis
  publication-title: Dig Dis Sci
– volume: 39
  start-page: 432
  year: 2019
  end-page: 441
  article-title: Effects of antibiotic therapy in primary Sclerosing cholangitis with and without inflammatory bowel disease: a systematic review and meta‐analysis
  publication-title: Semin Liver Dis
– volume: 66
  start-page: 611
  year: 2016
  end-page: 619
  article-title: The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls
  publication-title: Gut
– volume: 55
  start-page: 941
  year: 2020
  end-page: 950
  article-title: Open‐label prospective therapeutic clinical trials: oral vancomycin in children and adults with primary sclerosing cholangitis
  publication-title: Scand J Gastroenterol
– volume: 14
  start-page: 159
  year: 2021
  end-page: 164
  article-title: The role of oral vancomycin in inducing remission for biologic‐experienced ulcerative colitis with concomitant primary sclerosing cholangitis and liver transplantation
  publication-title: Clin J Gastroenterol
– volume: 328
  start-page: 2446
  year: 2022
  end-page: 2447
  article-title: Target trial emulation: a framework for causal inference from observational data
  publication-title: JAMA
– volume: 20
  start-page: 16
  year: 2018
  article-title: The IBD and PSC phenotypes of PSC‐IBD
  publication-title: Curr Gastroenterol Rep
– volume: 66
  start-page: 518
  year: 2017
  end-page: 527
  article-title: The natural history of primary sclerosing cholangitis in 781 children: a multicenter, international collaboration
  publication-title: Hepatology
– volume: 21
  start-page: 2065
  year: 2023
  end-page: 2075
  article-title: Recent advances in the management of primary sclerosing cholangitis
  publication-title: Clin Gastroenterol Hepatol
– ident: e_1_2_9_10_1
  doi: 10.1080/00365521.2020.1787501
– ident: e_1_2_9_26_1
  doi: 10.1136/gut.26.12.1380
– ident: e_1_2_9_29_1
  doi: 10.1001/jama.2022.21383
– ident: e_1_2_9_16_1
  doi: 10.1007/s12664-022-01286-9
– ident: e_1_2_9_14_1
  doi: 10.1093/ibd/izad040
– ident: e_1_2_9_4_1
  doi: 10.1016/j.cgh.2011.11.030
– ident: e_1_2_9_18_1
  doi: 10.1136/gutjnl-2018-316599
– ident: e_1_2_9_25_1
  doi: 10.1007/s10875-012-9801-1
– ident: e_1_2_9_2_1
  doi: 10.1016/j.jhep.2017.07.022
– ident: e_1_2_9_13_1
  doi: 10.1007/s12328-020-01296-0
– ident: e_1_2_9_24_1
  doi: 10.2147/CEG.S186097
– ident: e_1_2_9_6_1
  doi: 10.1136/gutjnl-2015-310500
– ident: e_1_2_9_3_1
  doi: 10.1007/s11894-018-0620-2
– ident: e_1_2_9_21_1
  doi: 10.1053/j.gastro.2020.12.058
– ident: e_1_2_9_22_1
  doi: 10.1136/gutjnl-2012-302578
– ident: e_1_2_9_9_1
  doi: 10.1055/s-0039-1688501
– ident: e_1_2_9_20_1
  doi: 10.1016/j.cgh.2023.04.004
– ident: e_1_2_9_7_1
  doi: 10.1007/s10620-023-07826-3
– ident: e_1_2_9_11_1
  doi: 10.1097/HEP.0000000000000304
– ident: e_1_2_9_30_1
  doi: 10.5223/pghn.2016.19.3.210
– ident: e_1_2_9_17_1
  doi: 10.1093/ibd/izz027
– ident: e_1_2_9_19_1
  doi: 10.1002/hep.29204
– ident: e_1_2_9_27_1
  doi: 10.1093/ibd/izz298
– ident: e_1_2_9_5_1
  doi: 10.3748/wjg.v26.i21.2768
– ident: e_1_2_9_8_1
  doi: 10.1002/hep.31560
– ident: e_1_2_9_12_1
  doi: 10.1007/s12328-020-01272-8
– ident: e_1_2_9_23_1
  doi: 10.3389/fimmu.2022.829525
– ident: e_1_2_9_15_1
  doi: 10.1097/MEG.0000000000001223
– ident: e_1_2_9_28_1
  doi: 10.1097/HC9.0000000000000347
SSID ssj0006702
Score 2.5163403
Snippet Summary Background Data on oral vancomycin for primary sclerosing cholangitis (PSC)‐associated inflammatory bowel disease (IBD) are limited. Aims Using data...
Data on oral vancomycin for primary sclerosing cholangitis (PSC)-associated inflammatory bowel disease (IBD) are limited. Using data from the Paediatric PSC...
BackgroundData on oral vancomycin for primary sclerosing cholangitis (PSC)‐associated inflammatory bowel disease (IBD) are limited.AimsUsing data from the...
Data on oral vancomycin for primary sclerosing cholangitis (PSC)-associated inflammatory bowel disease (IBD) are limited.BACKGROUNDData on oral vancomycin for...
BackgroundData on oral vancomycin for primary sclerosing cholangitis (PSC)-associated inflammatory bowel disease (IBD) are limited.AimsUsing data from the...
SourceID hal
proquest
crossref
pubmed
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 1236
SubjectTerms Cholangitis
Consortia
Endoscopy
Hemoglobin
Inflammatory bowel disease
Inflammatory bowel diseases
Intestine
Life Sciences
Pediatrics
Remission
Remission (Medicine)
Sensitivity analysis
Vancomycin
Title Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis‐associated inflammatory bowel disease (PSC‐IBD): A matched analysis from the Paediatric PSC Consortium
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fapt.17936
https://www.ncbi.nlm.nih.gov/pubmed/38462727
https://www.proquest.com/docview/3043896678
https://www.proquest.com/docview/2955268462
https://hal.univ-lille.fr/hal-04690334
Volume 59
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZKD4gLUJ4LLRoQh3JIFcd5mZ6WlmpBFFbQSj0gRbZjixXspmo2IHriJ_AbkfgfzDgPWhAIcUvsiZ3EM-MZe_wNYw91Yo3TRgc8clEQu8wE0nAeKBemkbGGZz434P7LdHIYPz9KjlbYdn8WpsWHGBbcSDK8viYBV7o-I-TqmBLqSkFw21xkFM63-_ondFSa-XhDdDFkEOVcdKhCFMUzPHluLrrwjiIhfzczz1utftrZu8Le9i_cRpu832qWesuc_oLl-J9fdJVd7sxRGLf8s8ZW7OIau7jfbbhfZ99fnWA1hQlU889YBLMaVDeitgRaxYWZX5fAO2RW5K-537cHXX2yH6Db_4H-ACZUzRKbsjUSw3GLdAE1do0_CCdR8K42pVCa1d--fD3T01_a3py-2UHiZ092Hz2GMSANMmIJqoNbATpBA2jnwlT1eUkAHwHKVYrOx6yZ32CHe08PdiZBlxkiMALVd4BqyUSZEyY2pVNJaJPcWa61CNHXV7Kk876pUjrMrc6kk9xInRJ2v9YmCV0pbrLVRbWwtxlkTqPFjHrLKB4bHqvEotEWWqlyk8iSj9iDnkeK7rcUveOEA1b4AUMi5J6hniC7J-MXBZX59Qch4o_Y0nrPXEWnKOpC0E4supxZPmL3h2oUcdq3UQtbNXURycSD8qTRiN1qmXLoSlAx2qAjtulZ68_vWIynB_7izr-T3mWXIjTi2gDPdba6PGnsBhphS33PS9sPhMQ0NQ
link.rule.ids 230,314,780,784,885,1375,27924,27925,46294,46718
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR3LbtQw0GqLBL3wpl0oMCAO5ZAqjvMy4rK0VFvYLSvYSr2gyHZsdQW7qZpNKzjxCXwjEv_B2HnQgkCIW2JP7CSeGc_LM4Q8kZFWRirp0cAEXmgS5XFFqSeMHwdKK5q42oCj_XhwEL46jA6XyPP2LEydH6IzuFnKcPzaErg1SJ-jcnFsK-pyFi-TS0ju1AZ07bz9mTwqTlzEISoZ3AtSypq8QjaOp3v0wm60fGRjIX8XNC_KrW7j2b1G3revXMebfNiqFnJLff4lm-P_ftN1crWRSKFfo9ANsqTnN8nlUeNzv0W-vznBbhspUMw-YRNMSxDNouocrCEXps40gXeIr4hiM-e6B1mc6Y_QuICgPYMJRbXAoXSJwHBcJ7uAEqfGP4T7KDht21ZRmpbfvnw9N9Nfxt4cv9tG4L0XO0-fQR8QBnExB9FkXAF7iAZQ1IWxaEuTAD4Ctlwp6h_TanabHOy-nGwPvKY4hKcYcnAPOZMKEsNUqHIjIl9HqdFUSuajui94bo_8xkJIP9Uy4YZTxWVs0_dLqSLf5OwOWZkXc71OIDEShWZkXUrQUNFQRBrlNl9zkaqI57RHHrdIkjW_JWt1J1ywzC0YAiH6dP02a_egP8xsmzNBMBae4kgbLXZlDa8oM2adsah1JmmPPOq6kcqt60bMdVGVWcAjl5cnDnpkrcbKbipmm1EM7ZFNh1t_fsesP564i7v_DvqQXBlMRsNsuLf_-h5ZDVCmq-M9N8jK4qTS91EmW8gHjvR-AKMYOFY
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELbaIlVcKG-WFhgQh3JIFcd5GU5Ll9UW2rKCVuoBKbIdW12V3ayaTSs48RP4jUj8D8bOgxYEQtwSe2In8cx4xh5_Q8hTGWllpJIeDUzghSZRHleUesL4caC0oonLDbi3H48Ow9dH0dESedGehanxIboFNysZTl9bAZ_n5oKQi7lNqMtZvEyuhHHALXD-4N1P7Kg4cQGH6GNwL0gpa2CFbBhP9-ilyWj52IZC_m5nXjZb3bwzXCMf2jeuw01OtqqF3FKffwFz_M9Puk6uNfYo9GsGukGW9OwmWd1rdtxvke9vT7HaxgkU009YBJMSRDOkOge7jAsTtzCBd8ityGBTt3EPsjjXH6HZAIL2BCYU1QKb0iUSw7yGuoASu8YfhLMoOF_b5lCalN--fL3Q01_a3hy_30binZeDZ8-hD0iDnJiDaPBWwB6hATR0YSzaxCSAj4BNVorex6Sa3iaHw1cH2yOvSQ3hKYb620O9pILEMBWq3IjI11FqNJWS-ejsC57bA7-xENJPtUy44VRxGVvwfilV5Juc3SErs2Km7xFIjESTGRWXEjRUNBSRRqvN11ykKuI57ZEnLY9kzW_JWs8JByxzA4ZEyD1dvcXsHvV3M1vmFiAYC8-wpY2WubJGU5QZs1ux6HMmaY887qpRxu3GjZjpoiqzgEcOlScOeuRuzZRdV8wWoxHaI5uOtf78jll_fOAu7v876SOyOh4Ms92d_Tfr5GqABl0d7LlBVhanlX6ABtlCPnSC9wPjLTcF
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Oral+vancomycin+is+associated+with+improved+inflammatory+bowel+disease+clinical+outcomes+in+primary+sclerosing+cholangitis%E2%80%90associated+inflammatory+bowel+disease+%28PSC%E2%80%90IBD%29%3A+A+matched+analysis+from+the+Paediatric+PSC+Consortium&rft.jtitle=Alimentary+pharmacology+%26+therapeutics&rft.au=Ricciuto%2C+Amanda&rft.au=Liu%2C+Kuan&rft.au=Wael+El%E2%80%90Matary&rft.au=Amin%2C+Mansi&rft.date=2024-05-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=0269-2813&rft.eissn=1365-2036&rft.volume=59&rft.issue=10&rft.spage=1236&rft.epage=1247&rft_id=info:doi/10.1111%2Fapt.17936&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0269-2813&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0269-2813&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0269-2813&client=summon